Clinical Trials Browser

Phase 4 × Ipilimumab × Dermatologic × Clear all

NCT07504796 2026-04-21

ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab

Phase 4 Recruiting

Melanoma

NCT01856023 2023-12-05

PROCLIVITY02

Phase 4 Terminated

29 enrolled 9 charts

Melanoma, Neoplasm Metastasis, Skin Neoplasms

NCT02068196 2023-03-24

Ipi4

Phase 4 Active not recruiting

Melanoma, Neoplasms